Electric mobility, drones, bulk drugs to contribute $170 bn to manufacturing by 2025-26: DIPP working group

NEW DELHI: Biotechnology, electric mobility, unmanned aerial vehicles and bulk drugs are among the eight emerging sectors that will contribute $170 billion to India’s manufacturing gross value added by 2025-26, a working group of the Department of Industrial Policy and Promotion (DIPP) has said.

Medical devices, robotics & automation equipment, advanced materials, and chemicals are the other emerging sectors that the group has identified to play a significant role in manufacturing.

“These sectors have exponential growth potential which need to be explored. Detailed assessment of the potential of these sectors should be taken up and actionable roadmaps drawn up to harness the potential,” said the working group on making India a $5 trillion economy by 2025 in its report.

Focus on emerging sectors is part of the three pronged strategy suggested by the group to achieve $1 trillion from manufacturing. Focus on existing high impact sectors and medium, small and micro enterprises (MSME) are the other two pillars.

Another $1 trillion from is expected to come from agriculture and allied activities while contribution from the services sector is pegged at $3 trillion.

The report has suggested an e-commerce policy and regulatory framework to strengthen the country’s logistics sector and using e-commerce to facilitate access to larger markets both domestic and international.

It said in the defence sector, there is a need to identify key components and systems and encourage global leaders to set up manufacturing base in India by offering limited period incentives; and ensure incentives result in technology/process transfer.

“Where applicable, leverage government purchases (Offset Policy), particularly for technology transfer; and ensure high-quality anchor investors capable of spurring growth of associated suppliers (including MSMEs) and offer limited period incentives to anchors, if required,” it said.

To boost electronics manufacturing, it said the government should consider offering additional fiscal incentives such as a limited-period tax holiday to players investing more than an identified threshold of investment. The report suggested measures to boost manufacturing in other areas including aeronautical, space, garments, organic and ayurvedic products.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’